EWTX Q3 2023 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$29M

Net Income

-$26M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$311M

Total Liabilities

$21M

Stockholders' Equity

$290M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$29M	-$18M	-61.3%
Net Income	-$26M	-$17M	-46.9%